// App-Quantinova.ai

NCOG-13 : BEVACIZUMAB IN IDH WILD TYPE ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA: A REAL WORD STUDY IN CHINA

Researchers

Presenter

  • Run Cui

Principal Investigators

  • Chengcheng Guo

  • Qunying Yang

  • Yonggao Mou

Medical Centers

  • Department of Neurosurgery, State Key Laboratory of Oncology in South China & Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China., Guangzhou, Guangdong, China (People's Republic)

  • Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China (People's Republic)

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Glioblastoma

  • Solid malignancies

  • Acro–dermato–ungual–lacrimal–tooth (ADULT) syndrome

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Temozolomide

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved